Since high levels of p-Nrf2 are commonly linked to the upregulation of antioxidant response factors, we evaluated how each treatment, CXB, TMZ, or their combination, affected the antioxidant defense capacity of GBM cells. The gene discussed is NFE2L2; the disease is glioblastoma.